CRBU (Caribou Biosciences) Beta: 2.9977 (As of Jun. 25, 2026)


CRBU Caribou Biosciences Inc CRBU
66 GF Score
Price $1.64
GF Value $1.70
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Beta?

Caribou Biosciences CRBU -1.41% 66 Beta is 2.9977 as of Jun. 25, 2026. GuruFocus rates CRBU with a GF Score™ of 66/100 and a GF Value™ of $1.70 (Fairly Valued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Caribou Biosciences's Beta is 2.9977.


Caribou Biosciences  (NAS:CRBU) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Caribou Biosciences Beta Related Terms


Caribou Biosciences Beta Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Beta Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 2.41 4.00

Caribou Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.40 2.56 3.43 4.00 3.19

CRBU vs OBIO, VYGR, WHWK: Beta Comparison

For the Biotechnology subindustry, Caribou Biosciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caribou Biosciences Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Beta distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's Beta falls into.


CRBU
66GF Score
Caribou Biosciences Inc CRBU
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.9977 mean?
Caribou Biosciences (CRBU) has a Beta of 2.9977 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Caribou Biosciences and its competitors.
Is Caribou Biosciences' Beta too high?
Caribou Biosciences' current Beta is 2.9977. Overall, Caribou Biosciences has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Beta compare to OBIO and VYGR?
Caribou Biosciences' Beta of 2.9977 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Caribou Biosciences and its competitors. Caribou Biosciences's current Beta is 2.9977. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.70, compared to a current price of $1.64 — trading 3.8% below its estimated fair value. The current Beta is 2.9977. Caribou Biosciences' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Beta is 2.9977 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued. The current stock price of $1.64 is trading 3.8% below its estimated GF Value™ of $1.70. GuruFocus considers Caribou Biosciences to be Fairly Valued.

Key valuation signals for CRBU:

  • Beta: 2.9977
  • GF Value™: $1.70 vs. price of $1.64 (3.8% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
66GF Score

Get the complete analysis for CRBU

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.64
Price
$1.70
GF Value